----

----

**UNITED      STATES**

**SECURITIES      AND EXCHANGE COMMISSION**

**Washington,      D.C. 20549**

----

**FORM      10-Q/A**

| **x** | **QUARTERLY                REPORT PURSUANT TO SECTION 13 OR 15(d)****OF                THE SECURITIES EXCHANGE ACT OF                1934** |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------|

**For      the quarterly period ended September 30, 2006**

**or**

| **o** | **TRANSITION                REPORT PURSUANT TO SECTION 13 OR****15(d) OF                THE SECURITIES EXCHANGE ACT OF                1934** |
|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

**For      the transition period from _______ to ___________**

**Commission      File Number 000-51169**

**ASPREVA      PHARMACEUTICALS CORPORATION**

----

| **British                Columbia, Canada**(State                or other jurisdiction ofincorporation                or organization) | **98-0435540**(I.R.S.                EmployerIdentification                No.) |
|----------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------|

**1203      - 4464 Markham Street, **

**Victoria,      British Columbia, **

**Canada      V8Z 7X8**

**(250)      744-2488**

| Large                Accelerated Filer o | Accelerated                Filer o | Non-accelerated                Filer x |
|------------------------------------------|------------------------------------|----------------------------------------|

----

----

----

**INDEX**

|                                | **Page** |
|-------------------------------------|----------|
|                                |     |
|                                |     |
| EXPLANATORY                    NOTE | 2        |
| Item                    6. Exhibits | 3        |
| SIGNATURE                           | 4        |

**EXPLANATORY          NOTE**

----

**PART          II - OTHER INFORMATION**

**ITEM 6.          EXHIBITS.**

| 10.28(1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Employment                    agreement between Aspreva Pharmaceuticals Corporation and Dr.                    Richard                    Jones effective March 6, 2006, as amended on October 24,                    2006.                                                                                                                                    |
|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.29(2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Change                    of control agreement, between Aspreva Pharmaceuticals Corporation                    and Dr.                    Richard Jones, effective March 6, 2006.                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 10.30(3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Employment                    agreement between Aspreva Pharmaceuticals Corporation and Mr.                    Charles F.                    Goulburn, effective October 18, 2004, as amended on October 23,                    2006.                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 10.31(3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Change                    of control agreement between Aspreva Pharmaceuticals Corporation                    and Mr.                    Charles F. Goulburn, effective October 24, 2006.                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 31.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Executive Officer, as required by Rule 13a-14(a)                    of the                    Securities and Exchange Act of 1934, as amended.                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 31.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Financial Officer, as required by Rule 13a-14(a)                    of the                    Securities and Exchange Act of 1934, as amended.                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 32.1*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Executive Officer, as required by Rule 13a-14(b)                    of the                    Securities and Exchange Act of 1934, as amended and Section 1350                    of                    Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section                    1350).            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 32.2*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Financial Officer, as required by Rule 13a-14(b)                    of the                    Securities and Exchange Act of 1934, as amended  and Section                    1350 of Chapter 63 of Title 18 of the United States Code (18                    U.S.C.                    Section 1350). |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| (1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Filed                    as the like numbered exhibit to our Quarterly Report on Form                    10-Q filed                    with the U.S. Securities and Exchange Commission on November                    9, 2006 and                    incorporated herein by reference.                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Filed                    as the like numbered exhibit to our Current Report on Form 8-K,                    dated July                    11, 2006, and filed with the U.S. Securities and Exchange Commission                    on                    July 17, 2006 and incorporated herein by reference.       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| (3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | Filed                    as the like numbered exhibit to our Current Report on Form 8-K,                    dated                    October 19, 2006, and filed with the U.S. Securities and Exchange                    Commission on October 25, 2006 and incorporated herein by                    reference. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |                                                                                                                                                                                                                                                                                                              |
| *                    The                    certifications attached as Exhibits 32.1 and 32.2 accompanied                    our                    Quarterly Report on Form 10-Q filed with the U.S. Securities                    and Exchange                    Commission on November 9, 2006, are not deemed filed with the                    Securities                    and Exchange Commission and are not to be incorporated by reference                    into                    any filing of Aspreva Pharmaceuticals Corporation under the Securities                    Act                    of 1933, as amended, or the Securities Exchange Act of 1934,                    as amended,                    whether made before or after the date of the Form 10-Q, irrespective                    of                    any general incorporation language contained in such                    filing. |

----

**SIGNATURE**

|                                 | ASPREVA                    PHARMACEUTICALS CORPORATION                   |   |
|--------------------------------------|-------------------------------------------------------------------------------|--------|
| November                    15, 2006 | /s/Bruce                    G. Cousins                                        |   |
|                                 | Bruce                    G. Cousins                                           |   |
|                                 | Chief                    Financial Officer and Executive Vice President  |   |
|                                 | (Principal                    Financial and Accounting Officer)               |   |

----

**EXHIBIT          INDEX**

| 10.28(1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                              | Employment                    agreement between Aspreva Pharmaceuticals Corporation and Dr.                    Richard                    Jones effective March 6, 2006, as amended on October 24,                    2006.                                                                                                                                    |
|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| 10.29(2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                              | Change                    of control agreement, between Aspreva Pharmaceuticals Corporation                    and Dr.                    Richard Jones, effective March 6, 2006.                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 10.30(3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                              | Employment                    agreement between Aspreva Pharmaceuticals Corporation and Mr.                    Charles F.                    Goulburn, effective October 18, 2004, as amended on October 23,                    2006.                                                                                                                          |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 10.31(3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |                                                                                                                                                                                                                                                                                                              | Change                    of control agreement between Aspreva Pharmaceuticals Corporation                    and Mr.                    Charles F. Goulburn, effective October 24, 2006.                                                                                                                                                                      |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 31.1                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Executive Officer, as required by Rule 13a-14(a)                    of the                    Securities and Exchange Act of 1934, as amended.                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 31.2                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Financial Officer, as required by Rule 13a-14(a)                    of the                    Securities and Exchange Act of 1934, as amended.                                                                                                                                                                   |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 32.1*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Executive Officer, as required by Rule 13a-14(b)                    of the                    Securities and Exchange Act of 1934, as amended and Section 1350                    of                    Chapter 63 of Title 18 of the United States Code (18 U.S.C. Section                    1350).            |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| 32.2*                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |                                                                                                                                                                                                                                                                                                              | Certification                    of the Chief Financial Officer, as required by Rule 13a-14(b)                    of the                    Securities and Exchange Act of 1934, as amended  and Section                    1350 of Chapter 63 of Title 18 of the United States Code (18                    U.S.C.                    Section 1350). |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |                                                                                                                                                                                                                                                                                                                                                           |
| (1)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Filed                    as the like numbered exhibit to our Quarterly Report on Form                    10-Q filed                    with the U.S. Securities and Exchange Commission on November                    9, 2006 and                    incorporated herein by reference.                           |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
| (2)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Filed                    as the like numbered exhibit to our Current Report on Form 8-K,                    dated July                    11, 2006, and filed with the U.S. Securities and Exchange Commission                    on                    July 17, 2006 and incorporated herein by reference.       |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
| (3)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          | Filed                    as the like numbered exhibit to our Current Report on Form 8-K,                    dated                    October 19, 2006, and filed with the U.S. Securities and Exchange                    Commission on October 25, 2006 and incorporated herein by                    reference. |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
|                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |                                                                                                                                                                                                                                                                                                              |
| *                    The                    certifications attached as Exhibits 32.1 and 32.2 accompanied                    our                    Quarterly Report on Form 10-Q filed with the U.S. Securities                    and Exchange                    Commission on November 9, 2006, are not deemed filed with the                    Securities                    and Exchange Commission and are not to be incorporated by reference                    into                    any filing of Aspreva Pharmaceuticals Corporation under the Securities                    Act                    of 1933, as amended, or the Securities Exchange Act of 1934,                    as amended,                    whether made before or after the date of the Form 10-Q, irrespective                    of                    any general incorporation language contained in such filing. |

----